{"prompt": "['Product: MK-3475', '122', 'Protocol/Amendment No.: 604-09', '10.6 Data Management', 'The investigator or qualified designee is responsible for recording and verifying the accuracy', 'of subject data. By signing this protocol, the investigator acknowledges that his/her', 'electronic signature is the legally binding equivalent of a written signature. By entering', 'his/her electronic signature, the investigator confirms that all recorded data have been', 'verified as accurate.', 'Detailed information regarding Data Management procedures for this protocol will be', 'provided separately.', '10.7 Publications', 'This trial is intended for publication, even if terminated prematurely. Publication may include', 'any or all of the following: posting of a synopsis online, abstract and/or presentation at a', 'scientific conference, or publication of a full manuscript. The Sponsor will work with the', 'authors to submit a manuscript describing trial results within 12 months after the last data', 'become available, which may take up to several months after the last subject visit in some', 'cases such as vaccine trials. However, manuscript submission timelines may be extended on', 'OTC trials. For trials intended for pediatric-related regulatory filings, the investigator agrees', 'to delay publication of the trial results until the Sponsor notifies the investigator that all', 'relevant regulatory authority decisions on the trial drug have been made with regard to', 'pediatric-related regulatory filings. Merk will post a synopsis of trial results for approved', \"products on www.clinicaltrials.gov by 12 months after the last subject's last visit for the\", 'primary outcome, 12 months after the decision to discontinue development, or product', 'marketing (dispensed, administered, delivered or promoted), whichever is later.', 'These timelines may be extended for products that are not yet marketed, if additional time is', 'needed for analysis, to protect intellectual property, or to comply with confidentiality', 'agreements with other parties. Authors of the primary results manuscript will be provided', 'the complete results from the Clinical Study Report, subject to the confidentiality agreement.', \"When a manuscript is submitted to a biomedical journal, the Sponsor's policy is to also\", 'include the protocol and statistical analysis plan to facilitate the peer and editorial review of', 'the manuscript. If the manuscript is subsequently accepted for publication, the Sponsor will', 'allow the journal, if it so desires, to post on its website the key sections of the protocol that', 'are relevant to evaluating the trial, specifically those sections describing the trial objectives', 'and hypotheses, the subject inclusion and exclusion criteria, the trial design and procedures,', 'the efficacy and safety measures, the statistical analysis plan, and any amendments relating to', 'those sections. The Sponsor reserves the right to redact proprietary information.', 'For multicenter trials, subsequent to the multicenter publication (or after public disclosure of', 'the results online at www.clinicaltrials.gov if a multicenter manuscript is not planned), an', 'investigator and his/her colleagues may publish their data independently. In most cases,', 'publication of individual trial site data does not add value to complete multicenter results,', 'due to statistical concerns. In rare cases, publication of single trial site data prior to the main', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '123', 'Protocol/Amendment No.: 604-09', 'paper may be of value. Limitations of single trial site observations in a multicenter trial', 'should always be described in such a manuscript.', 'Authorship credit should be based on 1) substantial contributions to conception and design,', 'or acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising', 'it critically for important intellectual content; and 3) final approval of the version to be', 'published. Authors must meet conditions 1, 2 and 3. Significant contributions to trial', 'execution may also be taken into account to determine authorship, provided that', 'contributions have also been made to all three of the preceding authorship criteria. Although', 'publication planning may begin before conducting the trial, final decisions on authorship and', \"the order of authors' names will be made based on participation and actual contributions to\", 'the trial and writing, as discussed above. The first author is responsible for defending the', 'integrity of the data, method(s) of data analysis and the scientific content of the manuscript.', 'The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or', 'presentations regarding this trial 45 days prior to submission for publication/presentation', 'Any information identified by the Sponsor as confidential must be deleted prior to', 'submission; this confidentiality does not include efficacy and safety results. Sponsor review', 'can be expedited to meet publication timelines.', '11.0 LIST OF REFERENCES', '[1]', 'Disis ML. Immune regulation of cancer. J Clin Oncol 2010;28(29):4531-8.', '[2]', 'Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-', 'associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune', 'evasion. Nat Med 2002;8(8):793-800.', '[3]', 'Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol', '2002;2(2):116-26.', '[4]', 'Brown JA, Dorfman DM, Ma F-R, Sullivan EL, Munoz O, Wood CR, et al.', 'Blockade of programmed death-1 ligands on dendritic cells enhances T cell', 'activation and cytokine production. J Immunol 2003;170(3):1257-66.', '[5]', 'Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and', 'autoimmunity. Immunol Rev 2010;236:219-42.', '[6]', 'Thompson RH, Dong H, Lohse CM, Leibovich BC, Blute ML, Cheville JC, et al.', 'PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor', 'outcome for patients with renal cell carcinoma. Clin Cancer Res 2007;13(6):1757-', '61.', '[7]', 'Hino R, Kabashima K, Kato Y, Yagi H, Nakamura M, Honjo T, et al. Tumor cell', 'expression of programmed cell death-1 ligand 1 is a prognostic factor for', 'malignant melanoma. Cancer 2010;116:1757-66.', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']\n\n###\n\n", "completion": "END"}